Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States

The adalimumab weekly dosing rate in a real-world, managed-care setting is less than that in clinical trials and academic centres. Geographic region and not starting on 160-/80-mg induction therapy were significantly associated with weekly adalimumab use for patients with CD.